Roche ends Huntington's drug program with Ionis Pharmaceuticals
What happened
Roche terminated the drug development partnership it held with Ionis Pharmaceuticals. This decision follows other clinical setbacks for Ionis, including the failure of Eplontersen to meet its primary endpoint in a Phase 3 study for treating transthyretin amyloid cardiomyopathy.
From fool.com
Why it matters
The termination materially damages Ionis Pharmaceuticals' pipeline and revenue. This event contributes to market scrutiny for pharmaceutical companies, particularly when compared to Alnylam Pharmaceuticals, which recently reported strong year-over-year revenue growth.
From fool.com
Who's involved
- Hoffmann-La RocheTerminated the drug development partnership with Ionis Pharmaceuticals.
- Ionis PharmaceuticalsLost the Huntington's drug program partnership with Roche.
- Alnylam PharmaceuticalsMentioned in financial comparison to Ionis Pharmaceuticals.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Ionis PharmaceuticalsSpeculative
Ionis Pharmaceuticals might see its revenue decline and pipeline risk increase due to the loss of the drug program.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
- Sanofi, Hoffmann-La Roche, Gilead, and Pfizer announced a collaboration to co-develop bexobrutideg, with Sanofi providing a $10M milestone payment.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
-
Ionis Pharmaceuticals
American pharmaceutical company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company